{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:12:19Z","timestamp":1794355939656,"version":"4.9.0"},"reference-count":80,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamaoncol.2019.5963","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T16:31:03Z","timestamp":1581611463000},"page":"764","source":"Crossref","is-referenced-by-count":56,"title":["An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice"],"prefix":"10.1001","volume":"6","author":[{"given":"Michael","family":"Rainone","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Mount Sinai St Luke\u2019s and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Mount Sinai St Luke\u2019s and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Salo-Mullen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia K.","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"crv190009r1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"crv190009r2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016.","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"crv190009r3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"crv190009r4","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations.","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6349","key":"crv190009r5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"30","key":"crv190009r6","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma.","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv190009r7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients.","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"crv190009r8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms.","volume":"110","author":"Lowery","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"crv190009r9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet Med"},{"issue":"23","key":"crv190009r10","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"crv190009r11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrgastro.2009.177","article-title":"Epidemiology of pancreatic cancer: an overview.","volume":"6","author":"Raimondi","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"crv190009r12","article-title":"Multigene hereditary cancer panels reveal high-risk pancreatic cancer susceptibility genes [published online July 25, 2018].","author":"Hu","journal-title":"JCO Precis Oncol"},{"key":"crv190009r13","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women [published online June 27, 2017].","author":"Kurian","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"crv190009r14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients.","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv190009r15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","article-title":"Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.","volume":"148","author":"Grant","year":"2015","journal-title":"Gastroenterology"},{"issue":"28","key":"crv190009r16","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma.","volume":"33","author":"Holter","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv190009r17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"17","key":"crv190009r18","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1002\/cncr.31628","article-title":"Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.","volume":"124","author":"Brand","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"crv190009r20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation.","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"crv190009r21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"crv190009r23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.18.01489","article-title":"Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion.","volume":"37","author":"Stoffel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7726","key":"crv190009r24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing.","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"issue":"7766","key":"crv190009r25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes.","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"key":"crv190009r26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2019.03.003","article-title":"Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: a scoping review.","volume":"75","author":"Singh","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"crv190009r27","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","article-title":"Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype.","volume":"23","author":"Lowery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"20","key":"crv190009r28","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of patients with pancreatic cancer: initial results from the Know Your Tumor initiative.","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"crv190009r29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"issue":"24","key":"crv190009r30","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer.","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"crv190009r32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2.","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"crv190009r33","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications.","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"crv190009r34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/humu.22262","article-title":"Cancer risks for MLH1 and MSH2 mutation carriers.","volume":"34","author":"Dowty","year":"2013","journal-title":"Hum Mutat"},{"issue":"1","key":"crv190009r35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/gim.0b013e31823375ea","article-title":"Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health\/clinical collaborative meeting.","volume":"14","author":"Bellcross","year":"2012","journal-title":"Genet Med"},{"issue":"4","key":"crv190009r36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/ejhg.2010.198","article-title":"Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.","volume":"19","author":"McWilliams","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"crv190009r37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.dld.2012.12.018","article-title":"Cancer risk associated with STK11\/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.","volume":"45","author":"Resta","year":"2013","journal-title":"Dig Liver Dis"},{"key":"crv190009r39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/nyas.1999.880.issue-1","article-title":"Hereditary pancreatitis and pancreatic carcinoma.","volume":"880","author":"Whitcomb","year":"1999","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"crv190009r40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer.","volume":"116","author":"Golan","year":"2017","journal-title":"Br J Cancer"},{"issue":"24","key":"crv190009r41","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX.","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"28","key":"crv190009r42","doi-asserted-by":"publisher","first-page":"19817","DOI":"10.18632\/oncotarget.v9i28","article-title":"Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.","volume":"9","author":"Kondo","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"crv190009r43","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"},{"issue":"10","key":"crv190009r44","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.","volume":"16","author":"Lowery","year":"2011","journal-title":"Oncologist"},{"issue":"4","key":"crv190009r45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2019.37.4_suppl.191","article-title":"Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: results from the Know Your Tumor (KYT) program.","volume":"37","author":"Pishvaian","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"crv190009r47","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers.","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"key":"crv190009r48","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation.","author":"Shroff","journal-title":"JCO Precis Oncol"},{"key":"crv190009r49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur J Cancer"},{"issue":"7","key":"crv190009r50","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/cncr.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.","volume":"124","author":"O\u2019Reilly","year":"2018","journal-title":"Cancer"},{"key":"crv190009r51","article-title":"A phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 [published online July 2019].","author":"Reiss Binder","journal-title":"Cancer Res"},{"issue":"4","key":"crv190009r52","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer.","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol"},{"issue":"67","key":"crv190009r53","doi-asserted-by":"publisher","first-page":"112103","DOI":"10.18632\/oncotarget.v8i67","article-title":"Hypermutation and microsatellite instability in gastrointestinal cancers.","volume":"8","author":"Yuza","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"crv190009r54","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1200\/JCO.2010.32.7825","article-title":"mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome.","volume":"29","author":"Kl\u00fcmpen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"crv190009r55","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.","volume":"12","author":"Min","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"crv190009r56","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"crv190009r57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMcp071286","article-title":"Clinical practice: management of an inherited predisposition to breast cancer.","volume":"357","author":"Robson","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"crv190009r58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","article-title":"ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes.","volume":"110","author":"Syngal","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"crv190009r61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/gim.2017.85","article-title":"Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.","volume":"20","author":"Chaffee","year":"2018","journal-title":"Genet Med"},{"issue":"3","key":"crv190009r62","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","article-title":"Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance.","volume":"155","author":"Canto","year":"2018","journal-title":"Gastroenterology"},{"issue":"17","key":"crv190009r63","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","article-title":"Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers.","volume":"34","author":"Vasen","year":"2016","journal-title":"J Clin Oncol"},{"key":"crv190009r64","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.14694\/EDBK_160391","article-title":"How far do we go with genetic evaluation? gene, panel, and tumor testing.","volume":"35","author":"Lynce","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"crv190009r65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.c.v178.1","article-title":"The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine.","volume":"178","author":"Stoll","year":"2018","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"6","key":"crv190009r66","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a002154","article-title":"The impact of hereditary cancer gene panels on clinical care and lessons learned.","volume":"3","author":"Okur","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"8","key":"crv190009r67","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1080\/07357900801956363","article-title":"Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.","volume":"26","author":"Casneuf","year":"2008","journal-title":"Cancer Invest"},{"issue":"9","key":"crv190009r68","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1055-9965.EPI-08-0460","article-title":"Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancer.","volume":"17","author":"Halfdanarson","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"crv190009r70","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1158\/1055-9965.EPI-08-0470","article-title":"Alcohol drinking and one-carbon metabolism-related gene polymorphisms on pancreatic cancer risk.","volume":"17","author":"Suzuki","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"crv190009r71","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1158\/1055-9965.EPI-08-0488","article-title":"Physical activity and pancreatic cancer risk: a systematic review.","volume":"17","author":"Bao","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"crv190009r72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10689-008-9214-8","article-title":"Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis.","volume":"8","author":"Permuth-Wey","year":"2009","journal-title":"Fam Cancer"},{"issue":"8","key":"crv190009r73","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/cncr.v113:8","article-title":"Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.","volume":"113","author":"Xiong","year":"2008","journal-title":"Cancer"},{"issue":"34","key":"crv190009r74","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","article-title":"Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing.","volume":"34","author":"Balma\u00f1a","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv190009r75","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jlb\/lsx038","article-title":"The known unknown: the challenges of genetic variants of uncertain significance in clinical practice.","volume":"4","author":"Hoffman-Andrews","year":"2018","journal-title":"J Law Biosci"},{"issue":"12","key":"crv190009r78","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/gim.2018.38","article-title":"False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.","volume":"20","author":"Tandy-Connor","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"crv190009r79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/gim.2015.190","article-title":"Direct-to-consumer genetic testing: a revised position statement of the American College of Medical Genetics and Genomics.","volume":"18","author":"ACMG Board of Directors","year":"2016","journal-title":"Genet Med"},{"issue":"7","key":"crv190009r80","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"key":"crv190009r19","author":"Taherian","year":"2019"},{"key":"crv190009r38","volume-title":"GeneReviews","author":"Schneider"},{"key":"crv190009r22","unstructured":"National Comprehensive Cancer Network. Pancreatic adenocarcinoma, version 2.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Published 2019. Accessed April 30, 2019."},{"key":"crv190009r31","unstructured":"Daly? MB, Pilarski? R, Berry? M, . Genetic\/familial high-risk assessment: breast and ovarian, version 3.2019. https:\/\/www.partnershipagainstcancer.ca\/db-sage\/sage20181503\/. Published 2019. Accessed July 25, 2019."},{"key":"crv190009r46","unstructured":"National Comprehensive Cancer Network. Pancreatic adenocarcinoma, version 1.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Published 2018. Accessed January 15, 2019."},{"key":"crv190009r59","unstructured":"US Preventive Services Task Force. Draft recommendation statement: pancreatic cancer: screening. https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/draft-recommendation-statement\/pancreatic-cancer-screening1. Published 2019. Accessed June 16, 2019."},{"key":"crv190009r60","unstructured":"US Preventive Services Task Force. Screening for pancreatic cancer: a systematic evidence review for the US Preventive Services Task Force. https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/draft-evidence-review\/pancreatic-cancer-screening1. Published February 2019. Accessed July 25, 2019."},{"key":"crv190009r69","unstructured":"Invitae Pancreatic Cancer Panel. Test description. https:\/\/www.invitae.com\/en\/physician\/tests\/01261\/. Accessed June 26, 2019."},{"key":"crv190009r76","unstructured":"ClinicalTrials.gov. A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma. NCT01983410. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01983410. Accessed July 25, 2019."},{"key":"crv190009r77","unstructured":"ClinicalTrials.gov. GENetic Education Risk Assessment and TEsting Study (GENERATE). NCT03762590. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762590. Accessed July 25, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2761195\/jamaoncology_rainone_2020_rv_190009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T09:46:35Z","timestamp":1614419195000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2761195"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.5963","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}